SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Nkarta, Inc. (NKTX) (CIK 0001787400) (NKTX) — Aug 18, 2021

Nkarta, Inc. (NKTX) (CIK 0001787400)
Date: Aug. 18, 2021 · CIK: 0001787400 · Accession: 0000000000-21-010126

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-258766

Date
August 18, 2021
Author
Paul Hastings
Form
UPLOAD
Company
Nkarta, Inc. (NKTX) (CIK 0001787400)

Letter

United States securities and exchange commission logo August 18, 2021 Paul Hastings Chief Executive Officer Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco, California 94080 Re:Nkarta, Inc. Registration Statement on Form S-3 Filed August 12, 2021 File No. 333-258766 Dear Mr. Hastings: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: C. Brophy Christensen, Jr.

Show Raw Text
United States securities and exchange commission logo
August 18, 2021
Paul Hastings
Chief Executive Officer
Nkarta, Inc.
6000 Shoreline Court, Suite 102
South San Francisco, California 94080
Re:Nkarta, Inc.
Registration Statement on Form S-3
Filed August 12, 2021
File No. 333-258766
Dear Mr. Hastings:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       C. Brophy Christensen, Jr.